A provider briefing on Camila 28 Day availability in 2026. Shortage timeline, prescribing implications, alternatives, and tools for your practice.
If your patients have been calling about difficulty filling their Camila 28 Day prescriptions, you're not alone. Progestin-only oral contraceptive availability has been inconsistent across pharmacies nationwide, creating prescribing challenges and patient anxiety. This briefing covers the current state of Camila 28 Day availability, its implications for clinical practice, and practical tools to help your patients maintain uninterrupted contraceptive coverage.
Camila 28 Day is a progestin-only oral contraceptive (POP) containing Norethindrone 0.35 mg, manufactured by Mayne Pharma. It is indicated for the prevention of pregnancy and is a critical option for patients who have contraindications to estrogen-containing contraceptives, including:
Norethindrone 0.35 mg works primarily by thickening cervical mucus and suppressing ovulation in approximately 50% of cycles. It requires strict adherence — patients must take it within the same 3-hour window daily, with backup contraception needed for 48 hours if a dose is delayed more than 3 hours.
Beginning in 2023, broader pharmaceutical supply chain pressures affected oral contraceptive availability across multiple manufacturers. While Norethindrone 0.35 mg was not placed on the FDA Drug Shortage list, individual brand availability — including Camila — became unpredictable at the pharmacy level.
Supply chains partially stabilized through 2025, but pharmacy-level availability remained inconsistent. Distributor contract changes caused some chains to rotate between Norethindrone brands (Camila, Errin, Heather, Jencycla), leading to patient confusion and frequent calls to prescribers' offices.
As of early 2026, Camila 28 Day is not listed on the FDA Drug Shortage database. Norethindrone 0.35 mg remains available from multiple generic manufacturers. However, the specific Camila brand may be intermittently unavailable at certain pharmacies depending on their distributor agreements. This is a distribution issue rather than a manufacturing shortage.
All Norethindrone 0.35 mg products are AB-rated generic equivalents. Pharmacists can substitute Errin, Heather, Jencycla, Jolivette, Nora-BE, Norlyda, Sharobel, Deblitane, or Incassia for Camila without a new prescription in most states, provided the prescription is written for Norethindrone or does not specify "dispense as written" (DAW).
Clinical recommendation: Consider writing prescriptions for "Norethindrone 0.35 mg" rather than the brand name "Camila" to give pharmacists maximum flexibility in filling from available stock.
Patients may express concern about switching brands. Key counseling points:
When patients experience gaps in supply, reinforce the critical importance of the 3-hour dosing window. Any delay beyond 3 hours requires 48 hours of backup contraception. Patients experiencing frequent supply disruptions may benefit from a switch to a method with less timing sensitivity.
Recommend these resources to patients struggling to find their medication:
Under the ACA contraceptive coverage mandate, most insured patients should receive Norethindrone at $0 cost-sharing. For uninsured patients:
No specific manufacturer patient assistance program exists for Camila from Mayne Pharma, but generic availability makes this less of a barrier.
For patients with recurring supply issues, consider transitioning to:
For a patient-facing version of these alternatives, direct patients to: Alternatives to Camila 28 Day.
The progestin-only contraceptive landscape continues to evolve. The availability of Opill (Norgestrel 0.075 mg) as the first OTC oral contraceptive provides another option for patients who face prescribing or pharmacy barriers. While it uses a different progestin and dosing schedule than Norethindrone, it may be appropriate for some patients.
Supply chain resilience for generic oral contraceptives is expected to continue improving through 2026–2027 as manufacturers expand production capacity. In the meantime, proactive prescribing strategies and patient education remain the most effective tools for maintaining contraceptive continuity.
Camila 28 Day availability issues in 2026 are primarily a distribution challenge, not a manufacturing shortage. By writing prescriptions generically, educating patients about brand equivalence, and leveraging tools like Medfinder for Providers, you can minimize disruptions to your patients' contraceptive care.
For patient-facing resources to share with your practice, see:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
